Based on the key indicators related to Galectin Therapeutics' liquidity, profitability, solvency, and operating efficiency, Galectin Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Galectin Therapeutics' Non Currrent Assets Other are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 31 M in 2025, whereas Common Stock Total Equity is likely to drop slightly above 35.5 K in 2025. Key indicators impacting Galectin Therapeutics' financial strength include:
The financial analysis of Galectin Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Galectin Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(35.11 Million)
Galectin
Select Account or Indicator
Market Cap
Enterprise Value
Dividend Yield
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Depreciation
Change To Liabilities
Stock Based Compensation
Total Cashflows From Investing Activities
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Good Will
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Property Plant And Equipment Net
Other Assets
Other Current Assets
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Property Plant Equipment
Current Deferred Revenue
Non Current Liabilities Total
Other Liab
Preferred Stock Total Equity
Long Term Debt
Retained Earnings Total Equity
Net Tangible Assets
Warrants
Capital Surpluse
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Gross Profit
Cost Of Revenue
Preferred Stock And Other Adjustments
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Galectin Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Galectin Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Galectin Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Galectin Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Galectin Therapeutics. Check Galectin Therapeutics' Beneish M Score to see the likelihood of Galectin Therapeutics' management manipulating its earnings.
Galectin Therapeutics Stock Summary
Galectin Therapeutics competes with Madrigal Pharmaceuticals, Viking Therapeutics, Sarepta Therapeutics, Hepion Pharmaceuticals, and PTC Therapeutics. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Galectin Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Galectin Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Galectin Therapeutics's current stock value. Our valuation model uses many indicators to compare Galectin Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galectin Therapeutics competition to find correlations between indicators driving Galectin Therapeutics's intrinsic value. More Info.
Galectin Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Galectin Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Galectin Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Galectin Therapeutics Systematic Risk
Galectin Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Galectin Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Galectin Therapeutics correlated with the market. If Beta is less than 0 Galectin Therapeutics generally moves in the opposite direction as compared to the market. If Galectin Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Galectin Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Galectin Therapeutics is generally in the same direction as the market. If Beta > 1 Galectin Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Galectin Therapeutics Thematic Clasifications
Galectin Therapeutics is part of Israel Wall Street investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Large Israel companies traded on major USA exchanges. Cross-sector collection of best publicly traded Israel entities that are expected to continue growing
This theme covers Large Israel companies traded on major USA exchanges. Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. Get More Thematic Ideas
Today, most investors in Galectin Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Galectin Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Galectin Therapeutics growth as a starting point in their analysis.
Galectin Therapeutics March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Galectin Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Galectin Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Galectin Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Galectin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Galectin Therapeutics's daily price indicators and compare them against related drivers.
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.